Loading page…

Makers Laboratories Ltd (MAKERSL) · mywealthgrid

About

Makers Laboratories Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹108 Cr

P/E

—

P/B

1.5×

Dividend yield

ROE

16.3%

ROCE

12.4%

Debt / equity

0.05

OPM

EPS (TTM)

₹-8.1

Book value

₹119.5

52-week high

₹220.9

52-week low

₹112.1

₹183.5+34.1%1Y

Beta

0.6

Damps index moves

Volatility (1y)

60%

Annualised, daily returns

RSI (14)

54.2

Neither overbought nor oversold

Rel. strength (1y)

22.5%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Profit CAGR of 29.9% over the last 3 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 12×
+High promoter holding of 61.3% with no pledge

Cons

−Low return on equity of 0.6% (3-yr avg)
−Thin operating margin of 7%
−Revenue shrank over the last 3 years (-1.7% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

68/100

Business quality: 51
Growth: 50

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	69	127	101	104	121
COGS	29	52	41	54	54
Gross profit	39	75	61	50	67
	31	56	57	49	58
Operating profit (EBITDA)	8	19	3	1	8
OPM %	11.8%	14.8%	3.2%	1%	7%
Depreciation	5	4	4	5	5
Interest	2	2	2	2	1
	1	3	2	2	11
Profit before tax	3	16	-1	-4	13
Tax	1	4	1	1	3
Tax %	50.4%	25.3%	160.7%	22.7%	18.6%
	1	12	-2	-5	11
PAT margin %	2%	9.2%	-2.2%	-4.6%	9%
EPS (₹)	-0.7	9.7	-7.9	-10.6	12.7
EPS adjusted (₹)	2.7	10.1	-8.1	-8.2	18.5
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	5	5	5	6	6	6
Reserves	—	49	55	63	57	65
Minority interest	—	32	39	40	41	45
	—	14	17	11	18	3
	—	35	29	31	39	29
Total equity & liabilities	—	136	144	152	161	148
	33	71	68	85	87	74
CWIP	—	0	9	0	0	1
Investments	—	2	0	0	3	0
	—	63	66	67	71	73
Total assets	—	136	144	152	161	148

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	5	19	-9	1	-4
	0	-22	1	-7	20
	0	0	6	6	-16
Net cash flow	5	-3	-2	-0	-0
Free cash flow	5	9	-22	-6	-8
CFO / Operating profit %	65%	98.6%	-265.2%	80%	-48.6%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	57.5%	58.7%	59.8%	47.9%	55.2%
EBITDA margin %	11.8%	14.8%	3.2%	1%	7%
EBIT margin %	5.1%	11.6%	-1%	-3.3%	3%
PAT margin %	2%	9.2%	-2.2%	-4.6%	9%
Working capital
Receivable days	88	39	72	70	84
Inventory days	344	166	281	227	230
Payable days	182	38	91	112	79
NWC days	250	167	262	184	234
Leverage
Current ratio	1.84	1.91	2.3	1.88	3.22
Debt to EBITDA	1.76	0.92	3.53	16.85	0.4
Debt to equity	0.26	0.29	0.17	0.28	0.05
Interest coverage	2.5	10.3	0.6	-1	12
Asset turnover	0.5	0.88	0.67	0.65	0.82
Return ratios
Return on assets %	1%	8.1%	-1.4%	-3%	7.4%
Return on capital employed %	4.3%	16.2%	1.1%	-1.6%	12.4%
Return on equity %	2.5%	19.7%	-3.2%	-7.6%	15.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%	61.27%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%	38.34%
No. of shareholders	—	—	—	—	—	—	—	—	4,026	3,926	3,801	3,745

Promoter holding up 0 percentage points since Sep 2023.

3 deals · 13 Mar 2023 – 20 May 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
20 May 2026	USHA JAWAHARLAL KALRO	Bulk	BSE	Buy	31,009	₹173.27	₹0.54 Cr
20 May 2026	USHA JAWAHARLAL KALRO	Bulk	BSE	Sell	26,158	₹180.25	₹0.47 Cr
13 Mar 2023	MANJU SINGHI	Bulk	BSE	Sell	29,562	₹105.75	₹0.31 Cr

1–3 of 3

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Raj Kamal Prasad VermaNon-Executive - Independent Director-Chairperson
Mr. Saahil ParikhExecutive Director-CEO
Mr. Nilesh JainExecutive Director
Ms. Dipti ShahNon-Executive - Independent Director
Mr. Vishal JainNon-Executive - Independent Director
Mr. Prashant GodhaNon-Executive - Non Independent Director
Mr. Piyush AjmeraCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Makers Laboratories Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

40 announcementsExport CSV

2 Jul 2026, 4:37 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Loading announcements…

Date	Category	Subject	Filing
2 Jul 2026, 4:37 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
23 Jun 2026, 1:31 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
9 Jun 2026, 12:30 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
27 May 2026, 4:52 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
27 May 2026, 1:30 pm	Company Update Reg.24(A)-Annual Secretarial Compliance	Compliances-Reg.24(A)-Annual Secretarial Compliance	PDF
26 May 2026, 12:57 pm	Result Financial Results	Standalone And Consolidated Results For FY 25-26	PDF
26 May 2026, 12:50 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Standalone And Consolidated Financial Results For FY 25-26	PDF
5 May 2026, 3:10 pm	Board Meeting	Board Meeting Intimation for Standalone And Consolidated Audited Financial Results For 4Th Quarter And Financial Year Ended 31St March, 2026	PDF

Makers Laboratories Ltd

Makers Laboratories Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

Credit ratings

7

1

No fund holdings on record

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Makers Laboratories Ltd

Makers Laboratories Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Dividends7

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

No fund holdings on record

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

7

1